Objectives: To characterize quantitatively the effect of avibactam in potentiating ceftazidime against MDR Pseudomonas aeruginosa by developing a mathematical model to describe the bacterial response to constant concentration time-kill information and validating it using both constant and time-varying concentration-effect data from in vitro and in vivo infection systems.
Introduction
Gram-negative bacterial multidrug resistance limits the availability of antibacterial options to treat infected patients. In particular, owing to the growth of resistance over the past two decades there has been a decrease in the proportion of clinically isolated Gramnegative bacteria that is susceptible to the anti-Gram-negative cephalosporin, ceftazidime. 1 Resistance to this compound is mostly caused by the bacterial production of serine-dependent blactamases of molecular classes A and C, although there are pockets of resistance caused by class B b-lactamases, which are metal dependent. A recently approved therapeutic intervention that has increased the potency of ceftazidime against MDR Gram-negative bacteria has been its combination with avibactam, an inhibitor of serine-dependent b-lactamases of classes A and C and some from class D. [2] [3] [4] [5] The Gram-negative spectrum of ceftazidime/avibactam activities excludes metallo-b-lactamase-positive bacteria because avibactam does not inhibit that class of b-lactamases. 6 Clinical use of ceftazidime/avibactam combination was licensed by the US FDA for the treatment of complicated intra-abdominal infections (cIAIs) and urinary tract infections (cUTIs) 7 and by the EMA for cIAIs, cUTIs, hospital-and ventilator-acquired pneumonia (HAP/ VAP) and aerobic Gram-negative infections with limited treatment options. 8 Avibactam inhibits the AmpC b-lactamase of Pseudomonas aeruginosa, including a broad range of genetic variants of that enzyme. 3 As a consequence, the in vitro spectrum of ceftazidime/ avibactam includes .90% of unselected clinical isolates of that species [9] [10] [11] and the combination is approved for clinical use against P. aeruginosa infections. 7, 8 In order to better understand the primary pharmacodynamics of ceftazidime/avibactam against P.
V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. aeruginosa, we have developed and tested a mathematical model of bacterial killing that predicts the exposure-response behaviour of individual isolates. The model was derived from experimental time-kill measurements with three ceftazidime-resistant clinical isolates of P. aeruginosa 12 and tested against four sets of previously published in vitro and in vivo exposure-response data that included studies of other strains of P. aeruginosa. [13] [14] [15] The study aimed to evaluate ceftazidime/avibactam activities by the following approach: (i) to characterize the time course of the growth and killing of three P. aeruginosa isolates and their b-lactamase activities monitored by ceftazidime degradation using a mechanistic model; and (ii) to evaluate the predictive ability of the pharmacodynamic model using simulated humanized dosing and compare the model predictions with bacterial killing from in vitro and in vivo infection models. External static time-kill data were from Keepers et al., 13 and external validation data for in vitro and in vivo infection models in which concentrations of both compounds varied over time were obtained from Crandon et al.
14 and Housman et al.
16

Materials and methods
Bacterial strains and time-kill kinetic studies
Throughout the present work, the term 'bacterial density' refers to number density, i.e. cfu/mL. The static time-kill kinetic studies of ceftazidime and avibactam combinations against three MDR clinical P. aeruginosa isolates 2154, 9750 and 10783 were reported previously. 12 The MICs of ceftazidime alone against these three isolates were 64, 256 and 128 mg/L, and the MICs of ceftazidime/avibactam (avibactam at 4 mg/L) were 4, 32 and 16 mg/L, respectively. The time-kill studies included a growth control, ceftazidime alone and ceftazidime/avibactam combinations in a chequerboard-type design. The concentration ranges for ceftazidime and avibactam were 2-512 mg/L and 2-16 mg/L, respectively, in 2-fold increments. Ceftazidime and avibactam concentrations were monitored for drug degradation during the course of the time-kill studies. The data for the pharmacodynamic model developed here came from these static time-kill kinetic studies. Concentrations of avibactam were stable throughout, so those data are not reported in detail and degradation kinetics were not modelled for that compound. Pharmacodynamic studies of ceftazidime/avibactam against two of these three isolates have also been reported elsewhere. Isolate 2154 was numbered 3607 in the work of Crandon et al.
14 and Housman et al., 16 and isolate 10783 was numbered 1388 (ARC3610) in those two studies and P. aeruginosa #7 by Berkhout et al.
15,17
Pharmacodynamic model development
The components of the pharmacokinetic/pharmacodynamic (PK/PD) model are illustrated in Figure 1 . The current model was modified from the model that characterized the bacterial response of Enterobacteriaceae to aztreonam/avibactam combination. 18 The detailed explanation of the in vitro PD model is available in the section 'In vitro pharmacodynamic model' in the Supplementary data (available at JAC Online). The description of the source data used in the external validation is described under the section 'Testing the model' in the Supplementary data.
Model prediction applied to the results from an in vitro hollow-fibre infection model
For applying the model developed here to the external hollow-fibre data set, 14 a steady-state one-compartment intravenous infusion profile was fitted to the ceftazidime and avibactam average concentration-time profiles targeted in that study.
14 The sampling-rich profile generated from the fitted model was used as input for the PD model. One thousand simulated bacterial dynamics were generated, wherein the residual variability was set to the values determined from the PD model. The time courses of bacterial response to the above regimen were plotted and compared with the results from the hollow-fibre study.
Simulation of the in vivo murine infection models
An in vivo PK model in humans was used to simulate concentration-time profiles after administration of 2 g ceftazidime and 0.5 g avibactam every 8 h as a 2 h intravenous infusion. 19 The resulting profiles were used to feed into the PD model to determine the 24 h bacterial density for the three bacterial strains used for the time-kill kinetic studies.
Important demographic and clinical characteristics affect the disposition of both ceftazidime and avibactam, including the patient's body weight, renal function and disease type. In order to take account of the impact of these covariates in the simulation and to yield realistic variances around the estimates of ceftazidime and avibactam concentrations at each time point in the modelling, patients' demographic and clinical parameters were first simulated, similar to work previously described for meropenem/fosfomycin combinations. 20 The detailed procedure for simulation of patients' demographic characteristics and population PK parameter values are described in the section 'Simulation of in vivo human pharmacokinetic model' in the Supplementary data.
The details of the population PK models of ceftazidime and avibactam, including structural model parameters, are provided in the Supplementary data (parameter values for inter-individual and residual variability are in Table S1 ). The mean and standard deviation of 1000 simulated concentration-time profiles were plotted and the mean and standard deviation for observed concentration-time profiles in mouse infection models were overlaid onto the simulated summary plots for comparison ( Figure S1 ). The concentration-time profiles of ceftazidime and avibactam from patients with normal renal function were used to predict 24 h bacterial densities simulating an initial inoculum of 10 6 cfu/tissue for the three P. aeruginosa isolates 2154, 10783 and 9750. In this simulation exercise, the residual variability in the PD model was set to 0. The change in 24 h bacterial density was computed and compared with those from murine infection models.
Results
PK/PD model building
A semi-mechanistic model is one that does not have all the biological definitions and processes that can be measured independently of the dataset referenced above but still captures the essence of the phenomenological observations from a set of experimental data. The semi-mechanistic PK/PD model presented here explicitly described the concentration dependence of growth and death of Table 1 . The logistic growth model incorporates a slowing of growth that depends on the difference between bacterial density and carrying capacity such that the growth rate constant becomes zero when this difference is zero. 21 The current model utilizes an additional sigmoidal E max relationship to describe the kill due to ceftazidime.
The fit of the mathematical model to the time-kill kinetic data was accomplished in several steps. A set of fitted parameters was only accepted when error minimization was successful. The initial fit of the model to the time-kill kinetics for any given ceftazidime/ avibactam combination assumed no drug degradation. The parameter estimates from that initial fit were then used to evaluate the effect of the bacterial population dynamics on the degradation of ceftazidime. In the second step, the parameters associated with bacterial growth and death in response to ceftazidime and avibactam concentrations were fixed at the values from the first step while the ceftazidime degradation and its inhibition by avibactam were fitted. The model for drug degradation considered that ceftazidime degradation was rapid when the active bacterial population approached a particular density and avibactam decreased the rate of drug degradation through an inhibitory E max model as a function of avibactam concentration (Supplementary data equation 5). This E max was set up as a proportionality function of the degradation rate and was bound between 0 and 1, such that the E max is 1 when the avibactam concentration is 0, i.e. no inhibition of ceftazidime degradation. As the avibactam concentration increased, the rate of ceftazidime degradation decreased. The estimated IC 50 of avibactam for inhibiting ceftazidime degradation was between 1 and 2 mg/L (Table 1) , which is consistent with the estimated avibactam threshold concentration reported in an in vivo study with P. aeruginosa 15 even though the IC 50 estimated here represented inhibition of bulk b-lactamase enzyme, whereas the avibactam threshold in vivo is assumed to reflect enhancement of the potency of ceftazidime at the individual bacterial cfu level.
Ceftazidime degradation was noticeably more rapid when the bacterial density approached 8-8.5 log 10 cfu/mL for all three P. aeruginosa isolates. The K m in Supplementary data equation (5) is the log 10 cfu/mL associated with 50% of the maximum degradation rate of ceftazidime. Candidate magnitudes of K m from 6 to 10 log 10 cfu/mL in increments of 0.5 were evaluated. When the K m value was set to 8.5 log 10 cfu/mL, the fit was considered acceptable. Optimization of the K m value could not be achieved Sy et al.
numerically owing to dependencies between parameters. Therefore, the K m value was taken as that which yielded the best fit by inspection to the degradation time course data plotted graphically. If the Hill coefficient for the degradation rate function (u in Supplementary data equation 5) is large (approximately 3), the K m can be interpreted as the P 1 density that switches on ceftazidime degradation. Isolate 2154 degraded ceftazidime relatively slowly (u , 3, Table 1 ). In contrast, the other two isolates, 10783 and 9750, degraded ceftazidime more rapidly, resulting in larger Hill coefficients (Table 1) . As can be seen in Figures 3 and 4 , for isolates 10783 and 9750 only 20% of the initial ceftazidime concentration remained after 6-12 h when the initial concentration was 32 or 64 mg/L in the absence of avibactam. Once the degradation model was fitted to the degradation data, it was combined with the bacterial population model by fixing the degradation-specific parameters. The parameter values presented in Table 1 are the final estimates of the integrated model, consisting of both the concentration-dependent time-kill model and the description of the drug degradation.
Testing predictions of the model against previously published data
In vitro
External validation of the derived model was achieved using data from previously published studies of the activity of ceftazidime/avibactam against MDR P. aeruginosa in vitro and in vivo. 13, 14, 16 The first external validation was to simulate constantconcentration time-kill kinetics yielded by 2, 4 and 8 mg/L ceftazidime in the presence of 4 mg/L avibactam with and without an additional 4 mg/L avibactam at 6 h against P. aeruginosa CML1040. 13 The initial inoculum size was 5.6 log 10 cfu/mL. 13 The MIC of ceftazidime alone against P. aeruginosa CML1040 was 64 mg/L and the MIC of ceftazidime with 4 mg/L avibactam was 1 mg/L. For the simulation exercise, the model parameters for P. aeruginosa 2154 were used because the MIC value of ceftazidime alone against this isolate was lowest among the three isolates whose data were used to build the model 12 and identical to the ceftazidime monotherapy MIC against P. aeruginosa CML1040. 
JAC
The results of the simulated 24 h bacterial density of P. aeruginosa 2154 compared with published time-kill data for isolate CML1040 are shown in Table 2 . The predicted 24 h bacterial densities in log 10 cfu/mL at various concentrations of ceftazidime between the two isolates were quite comparable at ceftazidime 2 and 4 mg/L although the model overestimated killing at ceftazidime 8 mg/L (Table 2 ). In the constant-concentration time-kill study of the three isolates that were used to develop the bacterial response model, 2 % MIC and 4 % MIC were associated with a significant reduction in bacterial density at 24 h. In contrast, the bacterial density at 24 h from the Keepers et al. study at 8 % MIC for the combination with and without additional 4 mg/L avibactam at 6 h still resulted in a net positive increase of 1.2 and 2.4 log 10 cfu/mL, respectively. 13 Thus the model parameters obtained for strain 2154 underestimated the regrowth observed with strain 3040 at higher ceftazidime concentrations. 13 This likely represented strainto-strain variation.
In the simulation exercise using the PD model derived in the present work, the concentration-time profiles of both drugs that were targeted in the three external studies of time-varying concentrations and bacterial growth-kill responses 13, 14, 16 were used as PK input to the time-kill PD model for the three P. aeruginosa isolates whose experimental data were used to construct the model. 12 Figure 5 shows the time courses of modelled bacterial responses of these three isolates to the simulated exposures of ceftazidime and avibactam. Time courses of bacterial responses from the hollow-fibre study of Crandon et al.
14 are overlaid onto the simulated response profiles in Figure 5 . The set of simulated kill curves for isolate 2154 overlaid the experimental PD data well for isolates against which the ceftazidime/avibactam MIC was 4 mg/L, i.e. the same as the MIC against the modelled isolate 2154 (Figure 5a 
In vivo
The model-predicted 24 h change in log 10 cfu/mL for isolates 2154, 10783 and 9750 to simulated patient exposures after 2 g ceftazidime and 0.5 g avibactam as a 2 h intravenous infusion every 8 h ( Figure S1 ) are shown in Figure 6 . Experimentally determined 24 h changes in log 10 cfu/mL in response to simulated patient exposures of ceftazidime and avibactam in a neutropenic mouse thigh infection model 14 and a neutropenic murine model of lung infection 16 are also shown ( Figure 6 ). The virtual response in isolate 2154 resulted in a net negative change in log 10 bacterial density after 24 h. The model predicted 2.5 log 10 kill of isolate 2154, against which the MIC was 4 mg/L; in the mouse experiments, strains testing with MIC 4 mg/L had comparable kill. The modelled isolates against which the ceftazidime/avibactam MICs were 16 and 32 mg/L showed, respectively, slight (0.2 log 10 ) or greater (1.5 log 10 ) virtual growth over 24 h, and in the in vivo experiments such isolates more frequently showed some growth than did isolates that tested with ceftazidime/avibactam MICs of 8 mg/L or lower ( Figure 6 ).
Discussion
Model development
The final model, consisting of a common structure but with varied parameters for the different isolates, fitted the experimental data for the three isolates well (Figures 2-4 ). This approach of using in vitro non-dynamic time-kill data to build bacterial growth-kill response models that can then be applied to time-dependent varying concentrations of a drug is well established. [22] [23] [24] [25] The pharmacological effect of the varying concentration of the b-lactamase inhibitor, avibactam, was modelled as a bi-exponential function. By shifting the EC 50 of the active drug, the additional parameters needed are significantly fewer, which improves model convergence and avoids nonidentifiability of model parameters.
26 Table 2 . Model-predicted and observed 24 h log 10 cfu/mL with starting inoculum of 5.7 log 10 cfu/mL (Table 1) . d Prediction intervals were generated from the residual variability of the PD model from 1000 simulations.
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There are cases in which the model predicted a shallower decrease in bacterial density than observed from the experimental time-kill kinetic data (Figures 2-4 ). This might be the same reason why the model predicted a shallower initial kill in isolates 10783 and 9750 compared with other strains used in the hollow-fibre study ( Figure 5 ). We implemented delays in both growth and kill in an attempt to allow a better fit to this initial killing pattern in the static time-kill studies.
14 In the comparison with the time-varying PK/PD data from the hollow-fibre study, the model did predict the initial observed kill, though more so with the more ceftazidime/avibactam-susceptible strain 2154 ( Figure 5 ). Compared with the implementation of delay in growth only, the dual delays resulted in a reduction of at least 50 units in the objective function value, which is a measure for model comparison based on maximum log-likelihood. The dual delay functions for both growth and kill also kept a tight correlation between the estimated EC 50 values and the MIC of ceftazidime at incremental avibactam concentrations ( Figure S6 ).
Testing the model against external data In vitro
The model partially fitted the previously published in vitro data, both for non-varying concentrations of ceftazidime and avibactam and for varying concentrations of these compounds (Table 2; Figure 5 ).The data from one isolate (isolate 1387) that tested with ceftazidime/avibactam MIC 8 mg/L deviated from the model prediction in that it was killed continuously when exposed to simulated patient exposures of ceftazidime and avibactam over 24 h in vitro 14 (Figure 5a) , whereas other isolates that tested with MICs of 8 mg/L were initially killed but then grew by the 24 h timepoint (Figure 5b and c) . The mechanism for this difference is unknown but the MIC of ceftazidime alone against the isolate that continued to be killed for 24 h was 32 mg/L, much lower than the MIC of ceftazidime against the other isolates (128 mg/L; 14 Figure 5a ).
In vivo
Bacterial responses over 24 h to varying concentrations of ceftazidime and avibactam from Monte Carlo simulations of patient PK were compared with bacterial responses to experimentally simulated patient exposures in neutropenic mouse thigh and lung infections ( Figure S1 ). 14, 16 The killing predicted by the model based on isolate 2154 (ceftazidime/avibactam MIC 4 mg/L) agreed qualitatively with the mouse data for isolates that tested with MIC 8 mg/L. It was not surprising that there was strain-to-strain variation in the degree of bacterial killing over 24 h. This might have been a result of variable expression of resistance and hence variable effects of ceftazidime and avibactam compared with those against strain 2154 in vitro. The variability might also have resulted from different degrees of susceptibility to the remaining host immune mechanisms in the neutropenic mice, noting that isolate JJ2-69 reproducibly grew in the thighs of neutropenic mice (although not in the lungs: strain 2-69) despite the ceftazidime and avibactam exposures, demonstrating one extreme of strainto-strain variability. 14, 16 Predictions for isolate 10783 differed from the data for that same isolate in the mouse studies in that little change in cfu/tissue was predicted, whereas 2 log 10 bacterial killing had been observed in both thigh and lung infections. The model prediction for the third isolate, 9750 (ceftazidime/avibactam MIC 32 mg/L), was also more conservative than the results in Ceftazidime/avibactam PK/PD model JAC the mouse infections observed for isolates that tested with the same MIC. That is, greater killing or less growth was observed in the mouse experimental models. The PD simulations, being based on in vitro data (Figures 2-4) , do not take into account the action of the residual immune system, which likely enhances the ceftazidime/avibactam killing effect in vivo. 15 Ceftazidime at clinically relevant concentrations can induce bacterial filament formation in P. aeruginosa. 27, 28 As soon as the ceftazidime concentration falls below a critical value, such filaments can rapidly septate and divide into multiple cfu, giving the appearance of rapid regrowth as inferred from monitoring cfu/mL. It is possible that some of the above discrepancies between the model based on in vitro exposures to ceftazidime and avibactam and the experimental time-varying exposures in vitro and in vivo from the other published studies was a result of different degrees of filament formation, and delayed division of such filaments, between the different studies. Experimental assessments of filament formation were not available from any of the studies, so this potential explanation was not examined further.
We have shown that the PK/PD model developed to describe the response to ceftazidime/avibactam of three P. aeruginosa isolates of different levels of ceftazidime resistance is quite versatile in its predictive performance and application to other isolates of similar magnitude in MIC values. The approach is similar to previous such exercises, including ones with other drugs and other bacterial species [29] [30] [31] [32] [33] [34] as well as examples with ceftazidime and P. aeruginosa. 22, 23 The new feature is the semi-mechanistic modelling of a b-lactamase inhibitor, avibactam, in combination with ceftazidime differently from the modelling of synergy between two antibacterial agents. 34 Avibactam had no intrinsic antipseudomonal activity, as shown in earlier observations. 9, 17, 35 The predictive performance of the current model was validated by both in vitro and in vivo experimental infection models using P. aeruginosa isolates with a wide range of resistance to ceftazidime, but also gaps in predictive ability were found. The current model, based on the in vitro growth kinetics data, was also used to evaluate the in silico predicted PD index of avibactam. The main conclusion, in agreement with the in vivo work of Berkhout et al., 15 was that time above critical concentration fitted the avibactam PD more closely than did AUC over critical concentration (S. K. B. Sy, L. Zhuang, H. Xia, V. J. Schuck, W. W. Nichols, H. Derendorf, unpublished data).
In conclusion, the current PK/PD model and modelled strains replicated the spread in activity reasonably well when compared against a large selection of P. aeruginosa strains, and the model could be extended to predict the behaviour of other P. aeruginosa isolates with varying dosing regimens of the ceftazidime/avibactam combination, bearing in mind that the predicted bacterial killing in vivo may be underestimated by the model.
Supplementary data
Further details of the in vitro pharmacodynamic model, Table S1 and Figures S1 to S6 appear as Supplementary data at JAC Online.
